Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-re... | Stopped
Efficacy and safety of retinal reju... | Stopped
Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related maculopathy
RETILASE

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Topic: Eye
  • Subtopic: Eye (all Subtopics)
  • Disease: Ophthalmology
Primary Contact Details
Recruitment Status
Stopped
Trial source and source ID number
ISRCTN87850962

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
Background and study aims
Age-related macular degeneration (AMD) is a leading cause of blindness amongst the elderly population and it is important to develop a preventative treatment for this disease. The aim of this study is to find out whether the 2RT laser is effective and safe as a new preventative treatment for early AMD.

Who can participate?
Patients aged 55 or over with AMD

What does the study involve?
Participants are randomly allocated to have either a one-off laser treatment or a sham treatment. Participants are followed up every 6 months for 2 years. In each visit, participants undergo vision tests and imaging of the eye.

What are the possible benefits and risks of participating?
If proven to be effective, the laser treatment may be an easy treatment to prevent the progression of early AMD to end-stage disease. The risk is the treatment may not work or it may provide too much energy or too little energy to produce the desired effect.

Where is the study run from?
King's College Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
December 2011 to June 2014

Who is funding the study?
J P Moulton Charitable Foundation (UK)

Who is the main contact?
Dr Sobha Sivaprasad
sobha.sivaprasad@nhs.net
Research Details
  • Age Related Macular Degeneration (AMD) is the leading cause of visual impairment amongst the elderly. In the United Kingdom, there is an estimated 608,213 patients diagnosed with AMD. This will increase to 755,867 by the end of the next decade, accounting for 22.5% of the ageing population.

    The clinical hallmark of AMD is the appearance of drusen which are localized deposits or debris lying between the basement membrane of the retinal pigment epithelium (RPE) and the Bruch's membrane. They are visible ophthalmoscopically as yellow-white deposits clustered mainly in the central macula. Although drusen alone do not account for significant loss of visual acuity in AMD, they can lead to deficits in macular function such as color contrast sensitivity and macular sensitivity. Approximately 10% of the eyes with drusen progress to the advanced forms of AMD every year. There are two main forms of advanced AMD: the geographic atrophy for which there are no treatment options and the neovascular subtype characterized by the development of choroidal neovascularization (CNV) that results in profound and rapid deterioration of vision and accounts for 80% of the blindness due to this condition. Given that AMD is the leading cause of blindness in the elderly despite the availability of costly drugs that are used to treat the advanced form (neovascular AMD), it is essential that preventive measures are available to delay progression of the disease to these advanced forms. The disease has to be curtailed at the early stages of the disease to prevent or reduce the impact on visual function. This project aims to use a minimally invasive laser technology to clear the aging retina of debris (drusen) so that the retina is rejuvenated making it less prone to the effects of multiple stressors that stimulate the progression to advanced AMD.

    More details can be found at http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=10926
Phase
Sorry, this information is not available
Study Design
Randomised; Interventional; Design type: Not specified
Study Type
Interventional
Intervention

The patients will be randomised to either have a one off laser treatment to the macula of one eye (2RT, nano second laser technology 400um spot size at least 25 spots) and the patients in the control arm receive only a sham laser. Patients will be followed up every 6 months for 2 years. In each visit, patients will have tests of visual function and imaging of the retina.

Intervention Type
Procedure/Surgery
Primary Outcome Measures
    Visual acuity; Timepoint(s): 1 year
Secondary Outcome Measures
    Not provided at time of registration
Publication(s)
Sorry, this information is not available
Result Reports
Sorry, this information is not available
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
Adult
Who Can Participate
Patient
Number of Participants
Planned Sample Size: 80; UK Sample Size: 80
Participant Inclusion Criteria
    1. Patients of either sex aged 55 years or over
    2. Diagnosis of age-related maculopathy that meet the criteria of large drusen (=125 µ) in at least 1 eye
    3. Best corrected visual acuity in the study eye between 50 to 90 ETDRS letters at baseline visit
    4. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs
    5. No previous macular laser therapy to study eye
    6. Written informed consent and willingness and ability to be followed up for 24 months
    Target Gender: Male & Female; Upper Age Limit 90 years; Lower Age Limit 55 years
Participant Exclusion Criteria
    1. Drusenoid PED, Choroidal neovascularisation and geographic atrophy in the study eye
    2. Macular ischaemia (FAZ > 1000µm in diameter or moderate perifoveal capillary loss in fluorescein angiogram) or diabetic retinopathy
    3. Macular oedema of any cause such as wet AMD, diabetic macular oedema, pseudophakic macular oedema or taut posterior hyaloid
    4. Co-existent ocular disease that in the investigator’s discretion would lead to decrease visual acuity by 3 lines or more by end of 12 months
    5. History of thermal lasers or treatment with intravitreal antiVEGF agents or steroids for any retinal conditions
    6. Participation in an investigational trial within 30 days of randomisation that involved treatment with any drug including those that has not received regulatory approval at the time of study entry
    7. Anticipated major ocular surgery (including cataract extraction) for the period of the trial
    8. Amblyopia in study eye
    9. Known allergy to fluorescein dye or to any component of the study drug
    10. Pregnancy at baseline and the patient will be withdrawn from the study if she becomes pregnant during the course of the study
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
King's College Hospital
London
SE5 9RS
Trial Contact(s)
Primary Trial Contact
Dr Sobha Sivaprasad
-
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related maculopathy (RETILASE trial)
EudraCT Number
Sorry, this information is not available
Funder(s)
  • J P Moulton Charitable Foundation (UK)
Other Study ID Numbers
10926
Sponsor(s)
King's College Hospital NHS Foundation Trust (UK)
Key Dates

Recruitment Start Date

15 Dec 2011

Recruitment End Date

22 Jun 2014

Trial Start Date

01 Dec 2011

Trial End Date

22 Jun 2014

Date added to source

20 Feb 2012

Date updated in source

07 Mar 2016